Panpharma
Manufacturer and distributor of sterile injectable medicines focused on hospital care. Operations include development, R&D, aseptic manufacturing, quality control and international distribution of injectable therapeutics across multiple sites in Europe.
Industries
Nr. of Employees
small (1-50)
Products
Heparin calcium — ampoules and prefilled syringes
Biologically derived anticoagulant product offered in multiple sterile presentations for subcutaneous administration (ampoules and prefilled syringes).
Injectable penicillins (sterile powders)
Sterile powder formulations for injectable penicillins produced with aseptic repartition and dedicated production equipment.
Injectable acetylsalicylic acid (hospital IV formulation)
Injectable presentation of acetylsalicylic acid marketed for hospital use following acquisition of national marketing authorisations.
Heparin calcium — ampoules and prefilled syringes
Biologically derived anticoagulant product offered in multiple sterile presentations for subcutaneous administration (ampoules and prefilled syringes).
Injectable penicillins (sterile powders)
Sterile powder formulations for injectable penicillins produced with aseptic repartition and dedicated production equipment.
Injectable acetylsalicylic acid (hospital IV formulation)
Injectable presentation of acetylsalicylic acid marketed for hospital use following acquisition of national marketing authorisations.
Services
Development, production and distribution services for sterile injectable medicines intended for hospital use; includes formulation, aseptic filling and batch release.
Development, production and distribution services for sterile injectable medicines intended for hospital use; includes formulation, aseptic filling and batch release.
Expertise Areas
- Injectable drug development and formulation
- Aseptic vial and prefilled syringe manufacturing
- Biologic injectables (heparin) production
- Quality control and analytical testing for injectables
Key Technologies
- Aseptic filling lines for vials
- Prefilled syringe filling and assembly
- Sterile powder repartition processing
- GMP equipment qualification and commissioning
News & Updates
Large-scale project (2022–2025) including new buildings and installation of production equipment dedicated to sterile powder repartition; development and equipment qualifications completed in June 2025.
Investment in a new automated vial filling line for injectable forms; launch scheduled for late 2025 after regulatory inspections and completion of qualification tests.
Acquired national marketing authorisation following prior European authorisations, enabling distribution of hospital injectable aspirin in Germany.
Public statement targeting a 50% reduction in greenhouse gas emissions by 2030 as part of ongoing RSE/RSE-like initiatives.
Recognition for regional economic involvement; company president attended an event at the Elysée Palace.
Selection as the sole producer of injectable antibiotics on French territory; planned investment to modernize production and double capacity at Luitré.
Large-scale project (2022–2025) including new buildings and installation of production equipment dedicated to sterile powder repartition; development and equipment qualifications completed in June 2025.
Investment in a new automated vial filling line for injectable forms; launch scheduled for late 2025 after regulatory inspections and completion of qualification tests.
Acquired national marketing authorisation following prior European authorisations, enabling distribution of hospital injectable aspirin in Germany.
Public statement targeting a 50% reduction in greenhouse gas emissions by 2030 as part of ongoing RSE/RSE-like initiatives.
Recognition for regional economic involvement; company president attended an event at the Elysée Palace.
Selection as the sole producer of injectable antibiotics on French territory; planned investment to modernize production and double capacity at Luitré.